Chemours (CC) Common Equity (2014 - 2026)

Chemours has reported Common Equity for 13 years, with the latest figure at -$49.0 million in Q2 2026.

• On a quarterly basis, Common Equity fell 121.3% year-over-year to -$49.0 million in Q2 2026; TTM through Jun 2026 was -$49.0 million, a 121.3% decrease from a year earlier, with the FY2025 full-year figure at $251.0 million, down 56.12% from the prior year.
• Common Equity was -$49.0 million for Q2 2026 at Chemours, down from $216.0 million in the prior quarter.
• The five-year high for Common Equity was $1.3 billion in Q3 2022, with the low at -$49.0 million in Q2 2026.
• Average Common Equity over 5 years is $692.3 million, with a median of $719.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Common Equity jumped 36.97% in 2022, then sank 121.3% in 2026.
• Over 5 years, Common Equity stood at $1.1 billion in 2022, then plunged by 34.63% to $723.0 million in 2023, then dropped by 20.89% to $572.0 million in 2024, then slumped by 56.12% to $251.0 million in 2025, then plunged by 119.52% to -$49.0 million in 2026.
• The last three Common Equity figures came in at -$49.0 million (Q2 2026), $216.0 million (Q1 2026), and $251.0 million (Q4 2025), per Business Quant data.